{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:05:56Z","timestamp":1782252356680,"version":"3.54.5"},"reference-count":90,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.eururo.2009.08.024","type":"journal-article","created":{"date-parts":[[2009,9,2]],"date-time":"2009-09-02T08:54:39Z","timestamp":1251881679000},"page":"60-70","source":"Crossref","is-referenced-by-count":180,"title":["An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously T1G3) Bladder Cancer"],"prefix":"10.1016","volume":"57","author":[{"given":"Girish S.","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver W.","family":"Hakenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Thalmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Kassouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Zlotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2009.08.024_bib1","unstructured":"Tyczynski JE, Parkin DM. Bladder cancer in Europe. European Network of Cancer Registries Web site. http:\/\/www.encr.com.fr\/bladder-factsheets.pdf. Updated September 2003. Accessed December 10, 2008."},{"key":"10.1016\/j.eururo.2009.08.024_bib2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Recurrence and progression of disease in non\u2013muscle-invasive bladder cancer: from epidemiology to treatment strategy","volume":"56","author":"van Rhijn","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The treated natural history of high risk superficial bladder cancer: 15-year outcome","volume":"158","author":"Cookson","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib4","unstructured":"Philips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-Based Medicine: levels of evidence. Centre for Evidence-Based Medicine Web site. http:\/\/www.cebm.net\/index.aspx?o=1025. Updated March 2009. Accessed August 5, 2009."},{"key":"10.1016\/j.eururo.2009.08.024_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1078-1439(01)00156-9","article-title":"The use of the marker tumor concept in Ta, T1 bladder cancer: is it justified?","volume":"7","author":"van der Meijden","year":"2002","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2009.08.024_bib6","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/ncpuro0917","article-title":"The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer","volume":"4","author":"Witjes","year":"2007","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib7","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0022-5347(05)65969-1","article-title":"Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy","volume":"166","author":"Dutta","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00005392-199907000-00018","article-title":"The value of a second transurethral resection in evaluating patients with bladder tumors","volume":"162","author":"Herr","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.eururo.2003.12.016","article-title":"A second-look TUR in T1 transitional cell carcinoma: why?","volume":"45","author":"Jakse","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib10","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0022-5347(05)67022-X","article-title":"The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials","volume":"164","author":"Van Der Meijden","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1040-8428(03)00073-8","article-title":"The new World Health Organization\/International Society of Urological Pathology (WHO\/ISUP) classification for TA, T1 bladder tumors: is it an improvement?","volume":"47","author":"Epstein","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eururo.2009.08.024_bib12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1464-410X.2006.06672.x","article-title":"A critical appraisal of the classification of urothelial tumours: time for a review of the evidence and a radical change?","volume":"99","author":"Harnden","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.08.024_bib13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1464-410X.2008.07538.x","article-title":"Does the current World Health Organization classification predict the outcome better in patients with noninvasive bladder cancer of early or regular onset?","volume":"102","author":"Burger","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.08.024_bib14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.eururo.2007.12.026","article-title":"Prediction of progression of non\u2013muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study","volume":"54","author":"Burger","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.08.024_bib16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib17","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials","volume":"171","author":"Sylvester","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.juro.2007.08.166","article-title":"A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences","volume":"179","author":"Berrum-Svennung","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0302-2838(03)00040-X","article-title":"The value of a second transurethral resection in evaluating patients with bladder tumours","volume":"43","author":"Miladi","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib20","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1464-410X.2006.06144.x","article-title":"The value of a second transurethral resection for T1 bladder cancer","volume":"97","author":"Schwaibold","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.08.024_bib21","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S0022-5347(05)66532-9","article-title":"Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?","volume":"165","author":"Brauers","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib22","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.urolonc.2007.05.002","article-title":"Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder","volume":"25","author":"Soloway","year":"2007","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2009.08.024_bib23","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0022-5347(05)00689-0","article-title":"Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer?","volume":"175","author":"Divrik","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.juro.2006.08.070","article-title":"Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?","volume":"177","author":"Herr","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib25","doi-asserted-by":"crossref","unstructured":"Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev 2000:CD001986.","DOI":"10.1002\/14651858.CD001986"},{"key":"10.1016\/j.eururo.2009.08.024_bib26","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.08.024_bib29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.08.024_bib30","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.eururo.2003.12.002","article-title":"TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years","volume":"45","author":"Serretta","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib31","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1445-2197.2004.02941.x","article-title":"Low dose BCG as adjuvant therapy for superficial bladder cancer and literature review","volume":"74","author":"Cheng","year":"2004","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.eururo.2009.08.024_bib32","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0022-5347(01)65458-2","article-title":"Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy","volume":"156","author":"Hurle","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000019664","article-title":"Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success","volume":"34","author":"Lebret","year":"1998","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer","volume":"89","author":"Martinez-Pineiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.08.024_bib35","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.urology.2007.11.080","article-title":"Low-dose instillation therapy with bacille Calmette-Guerin Tokyo 172 strain after transurethral resection: historical cohort study","volume":"71","author":"Yoneyama","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.08.024_bib36","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib37","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.eururo.2008.06.062","article-title":"Is maintenance Bacillus Calmette-Gu\u00e9rin really necessary?","volume":"54","author":"Herr","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib38","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/cncr.23627","article-title":"Maintenance bacillus Calmette-Guerin in high-risk nonmuscle-invasive bladder cancer: how much is enough?","volume":"113","author":"Decobert","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2009.08.024_bib39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0094-0143(05)70241-X","article-title":"Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer","volume":"27","author":"Dalbagni","year":"2000","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.eururo.2009.08.024_bib40","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0090-4295(99)00591-9","article-title":"Long-term results of intravesical bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer","volume":"55","author":"Brake","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.08.024_bib41","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","article-title":"Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib42","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0022-5347(05)65157-9","article-title":"Contemporary management of stage T1 transitional cell carcinoma of the bladder","volume":"167","author":"Soloway","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib43","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer","volume":"177","author":"Raj","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib44","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","article-title":"Management of stage T1 tumors of the bladder: International Consensus Panel","volume":"66","author":"Nieder","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.08.024_bib45","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2009.08.024_bib46","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2009.08.024_bib47","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study","volume":"66","author":"Bartoletti","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.08.024_bib48","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/sj.bjc.6604074","article-title":"Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study","volume":"97","author":"Gunelli","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2009.08.024_bib49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eururo.2004.01.019","article-title":"Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder","volume":"46","author":"van der Heijden","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2009.08.024_bib51","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(02)01920-9","article-title":"Impact of a second transurethral resection on the staging of T1 bladder cancer","volume":"60","author":"Dalbagni","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.08.024_bib52","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMsa012337","article-title":"Hospital volume and surgical mortality in the United States","volume":"346","author":"Birkmeyer","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2009.08.024_bib53","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2009.08.024_bib54","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1371\/journal.pmed.0040284","article-title":"Optimal management of high-risk T1G3 bladder cancer: a decision analysis","volume":"4","author":"Kulkarni","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.eururo.2009.08.024_bib55","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1464-410X.2005.05287.x","article-title":"Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy","volume":"95","author":"Wiesner","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.08.024_bib56","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib57","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2007.06.030","article-title":"Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?","volume":"53","author":"Denzinger","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1464-410X.2007.06912.x","article-title":"The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy","volume":"100","author":"Lambert","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.08.024_bib59","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib60","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1464-410X.2006.06624.x","article-title":"Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder","volume":"99","author":"Dalbagni","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.08.024_bib61","first-page":"829","article-title":"p53 and RB expression predict progression in T1 bladder cancer","volume":"4","author":"Grossman","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2009.08.024_bib62","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1200\/JCO.2006.05.8149","article-title":"Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?","volume":"24","author":"Weiss","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2009.08.024_bib63","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.juro.2007.05.024","article-title":"A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder","volume":"178","author":"Harland","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib64","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0022-5347(01)66043-9","article-title":"Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder","volume":"155","author":"Zhang","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib65","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1046\/j.1464-410X.1997.00431.x","article-title":"Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome","volume":"80","author":"Herr","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib66","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0090-4295(99)00116-8","article-title":"Intravesical bacille Calmette-Guerin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up","volume":"54","author":"Hurle","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.08.024_bib67","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0090-4295(98)00480-4","article-title":"Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder","volume":"53","author":"Gohji","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.08.024_bib68","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S0022-5347(05)67523-4","article-title":"Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin","volume":"163","author":"Brake","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib69","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0090-4295(01)01324-3","article-title":"Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years","volume":"58","author":"Patard","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.08.024_bib70","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0090-4295(01)01603-X","article-title":"Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience","volume":"59","author":"Pansadoro","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.08.024_bib71","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(01)01539-4","article-title":"Long-term maintenance bacille Calmette-Guerin therapy in high-grade superficial bladder cancer","volume":"59","author":"Iori","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.08.024_bib72","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1046\/j.1464-410X.2002.02969.x","article-title":"Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette-Guerin (Danish 1331 strain)","volume":"90","author":"Kulkarni","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.08.024_bib73","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/S0022-5347(05)64994-4","article-title":"Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance","volume":"167","author":"Griffiths","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib74","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-5347(05)64044-X","article-title":"A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival","volume":"169","author":"Shahin","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib75","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1442-2042.2003.00559.x","article-title":"Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder","volume":"10","author":"Hara","year":"2003","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib76","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1097\/01.ju.0000066840.42991.4a","article-title":"Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients","volume":"169","author":"Peyromaure","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib77","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1464-410X.2004.04556.x","article-title":"T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival","volume":"93","author":"Peyromaure","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.08.024_bib78","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0090-4295(98)00369-0","article-title":"Intravesical bacillus Calmette-Guerin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder","volume":"52","author":"Baniel","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.08.024_bib79","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.urology.2006.09.019","article-title":"Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by bacille Calmette-Guerin immunotherapy","volume":"69","author":"Margel","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.08.024_bib80","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.ju.0000132129.87598.3b","article-title":"Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?","volume":"172","author":"Thalmann","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib81","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/B:UROL.0000032688.37789.7c","article-title":"T1G3 bladder cancer\u2014indications for early cystectomy","volume":"36","author":"Masood","year":"2004","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2009.08.024_bib82","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1078-1439(03)00144-3","article-title":"Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy","volume":"22","author":"Bianco","year":"2004","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2009.08.024_bib83","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.urology.2007.10.041","article-title":"Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy","volume":"71","author":"Gupta","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.08.024_bib84","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.juro.2007.05.054","article-title":"The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer","volume":"178","author":"Divrik","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib85","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00005392-200101000-00011","article-title":"The predictive value of muscularis mucosae invasion and p53 overexpression on progression of stage T1 bladder carcinoma","volume":"165","author":"Bernardini","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib86","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2005.04.013","article-title":"Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a\/b\/c) in BCG-treated and BCG-non-treated patients","volume":"48","author":"Orsola","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib87","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/j.1464-410X.2006.06145.x","article-title":"A re-staging transurethral resection predicts early progression of superficial bladder cancer","volume":"97","author":"Herr","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2009.08.024_bib88","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)65168-3","article-title":"Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression","volume":"167","author":"Holmang","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib89","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.08.024_bib90","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2005.03.021","article-title":"Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor","volume":"48","author":"Huguet","year":"2005","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283809008926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283809008926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T10:02:41Z","timestamp":1558519361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283809008926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0302283809008926"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2009.08.024","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}